Answers are grounded in this paper and cite their sources.
Examines glucagon's influence on physiological outcomes in chick embryos, suggesting implications for metabolic regulation.
Various concentrations of glucagon (recorded in Table 1) were injected into the yolk mass of White Leghorn chicks on incubation days 8, 10 and 12. A study of the survival rates, weights, blood sugars, livers, tibiotarsi and pancreas from these and untreated embryos was undertaken for incubation days 8 to 16. The survival rates recorded in the present study indicate a "glucagon tolerance range" between 30.0 ug and 160.0 ug dosages. Glucagon treatment showed significant increases in mean body weights over both diluent-treated and untreated embryos indicating a direct stimulation. The blood sugar examinations demonstrated three general patterns. Firstly, the administration of glucagon on day 10 showed that the low concentrations produced hypoglycemia while the high concentrations produced hyperglycemia. Secondly, the administration of the high concentrations on day 8 caused hypoglycemia while administration of the same concentrations on day 10 led to the opposite effect, hyperglycemia. The 150.0 ug injection of glucagon produced hypoglycemia when administered on day 12. Thirdly, the low concentrations of glucagon produced long term hypoglycemia for both day 8 and 10 injections. Histochemically, glucagon caused significant increases in the liver glycogen storage and showed in the more severely effected embryos a direct correlation between chondrocyte glycogen and blood sugar levels. Histologically, pancreatic islet tissue showed an increase in beta islet tissue and a decrease in alpha islet tissue following glucagon treatment. The suggestion is made as a result of a comparison of the data collected in the present study with that recorded by Zwilling (1948) that the increased endogenous glucagon secretion recorded following insulin administration does not contribute to the development of the abnormal insulin patterns but functions in counteracting and reducing the effects of the insulin treatment.
No takes yet. Share an insight, caveat, or question.
William Athen Anderson (1976) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: